OA
OABI.US OmniAb Inc.
- Market cap
- USD 713M
- P/E
- -
- P/B
- 2.87x
- ROE
- -15.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OABI.US undervalued?
Graham numberThe Graham number of OmniAb Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OmniAb Inc. fundamental analysis
No fundamental analysis for OmniAb Inc. yet.
OmniAb Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powe…
Full company profileOmniAb Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OmniAb Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 18.3M | 23.3M | 34.7M | 59.1M | 34.2M | 26.4M | 18.7M | 42.4M |
| Gross Profit | 18.3M | 23.3M | 34.7M | 59.1M | 34.2M | 26.4M | -3.39M | 33.2M |
| Operating Income | -13.0M | -25.6M | -35.6M | -26.6M | -69.4M | -74.5M | -71.5M | -41.2M |
| EBITDA | -2.93M | -10.4M | -18.1M | -7.81M | -44.9M | -47.8M | -44.5M | -19.6M |
| Net Income | -13.6M | -17.6M | -27.0M | -22.3M | -50.6M | -62.0M | -64.8M | -39.0M |
| EPS | -0.12 | -0.15 | -0.24 | -0.26 | -0.51 | -0.61 | -0.57 | -0.30 |
| Balance Sheet | ||||||||
| Total Assets | 262M | 295M | 304M | 421M | 375M | 326M | 301M | 291M |
| Total Liabilities | 44.1M | 59.8M | 70.2M | 79.8M | 60.6M | 37.9M | 33.9M | 41.8M |
| Shareholders' Equity | 218M | 236M | 234M | 341M | 315M | 288M | 267M | 249M |
| Cash & Short-term Investments | - | -2.59M | -13.9M | 88.3M | 87.0M | 59.4M | 54.0M | 64.2M |
| Total Debt | 2.58M | 2.59M | 13.9M | 25.8M | 25.6M | 23.2M | 20.3M | 18.1M |
| Cash Flow | ||||||||
| Operating Cash Flow | -5.20M | 3.62M | -5.67M | -3.59M | 2.35M | -39.7M | -36.5M | 11.1M |
| Capital Expenditure | 255K | 1.75M | 4.07M | 17.2M | 1.64M | 1.88M | 565K | 369K |
| Free Cash Flow | -5.45M | 1.87M | -9.74M | -20.8M | 703K | -41.5M | -37.0M | 10.8M |
| Ratios | ||||||||
| ROE | -6.2% | -7.5% | -11.5% | -6.5% | -16.1% | -21.6% | -24.3% | -15.7% |
| ROA | -5.2% | -5.9% | -8.9% | -5.3% | -13.5% | -19.1% | -21.5% | -13.4% |
| Net Profit Margin | -74.2% | -75.5% | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% | -92.1% |
| Debt to Equity | 0.01x | 0.01x | 0.06x | 0.08x | 0.08x | 0.08x | 0.08x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
OmniAb Inc. dividends
OmniAb Inc. has not paid dividends in the last 7 fiscal years.
Who owns OmniAb Inc.
- Insiders 15.56%
- Institutions 55.75%
- Public & others 28.70%
- Shares outstanding 146M
- Free float 119M
Top funds holding OABI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 2.78M | 1.91% | 0.00% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.38M | 1.63% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 1.22M | 0.84% | +1.84% | Aug 2026 |
| iShares Russell 2000 Value ETF | 1.05M | 0.72% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 936K | 0.64% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 639K | 0.44% | +1.01% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 601K | 0.41% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 525K | 0.36% | -12.00% | Sep 2026 |
| CREF Total Global Stock Account R3 | 367K | 0.25% | -4.11% | Sep 2026 |
| iShares Micro-Cap ETF | 333K | 0.23% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap I | 276K | 0.19% | +1.66% | Sep 2026 |
| Schwab Small Cap Index | 266K | 0.18% | 0.00% | Sep 2026 |
| Canada Life US Small-Mid Cap Growth F | 263K | 0.18% | 0.00% | Aug 2026 |
| Vanguard Health Care ETF | 242K | 0.17% | +0.11% | Sep 2026 |
| Fidelity Total Market Index | 233K | 0.16% | -0.05% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 232K | 0.16% | +0.27% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 200K | 0.14% | -5.54% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 197K | 0.14% | +0.03% | Oct 2026 |
| Fidelity Series Total Market Index | 186K | 0.13% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 173K | 0.12% | -5.90% | Oct 2026 |
Top institutions holding OABI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Whitefort Capital Management, LP. | 10.2M | 7.03% | -27.95% | Jun 2026 |
| BlackRock Inc | 8.90M | 6.10% | +9.75% | Jun 2026 |
| Nomura Holdings Inc | 5.03M | 3.45% | +613.17% | Jun 2026 |
| Cadian Capital Management LP | 4.21M | 2.89% | +1.32% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.85M | 2.64% | -3.54% | Jun 2026 |
| Geode Capital Management, LLC | 2.88M | 1.98% | -1.42% | Jun 2026 |
| Rice Hall James & Associates, LLC | 2.61M | 1.79% | +2.48% | Jun 2026 |
| Private Management Group Inc | 2.34M | 1.61% | -3.47% | Jun 2026 |
| State Street Corp | 2.13M | 1.46% | +3.21% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.24M | 0.85% | -1.70% | Sep 2026 |
| Towerview LLC | 1.16M | 0.80% | -1.60% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 980K | 0.67% | +8.48% | Jun 2026 |
| Charles Schwab Investment Management Inc | 967K | 0.66% | +0.76% | Jun 2026 |
| Northern Trust Corp | 948K | 0.65% | +7.65% | Jun 2026 |
| ADAR1 Capital Management LLC | 947K | 0.65% | +34.35% | Jun 2026 |
| ISTHMUS Partners LLC | 802K | 0.55% | -0.16% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 758K | 0.52% | +4.53% | Jun 2026 |
| Renaissance Technologies Corp | 752K | 0.52% | +25.21% | Sep 2026 |
| Two Sigma Investments LLC | 657K | 0.45% | +28.22% | Jun 2026 |
| Nuveen, LLC | 643K | 0.44% | +3.04% | Jun 2026 |
OmniAb Inc. company profile
- Company name
- OmniAb Inc.
- Ticker
- OABI.US
- Exchange
- USA Stocks
- Listed since
- Nov 2, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 89
- Fiscal year end
- December
- Address
- 5980 Horton Street, EmeryVille, CA, United States, 94608
- Phone
- 510 250 7800
- Website
- omniab.com
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
OmniAb Inc. management
10- Mr. Matthew W. FoehrPresident, CEO & Director · born 1973
- Mr. Kurt A. GustafsonExecutive VP of Finance & CFO · born 1968
- Mr. Charles S. Berkman J.D.Chief Legal Officer · born 1969
- Mr. Amechi NwachukuExecutive VP & Chief Operating Officer · born 1975
- Ms. Cia McCaffreySenior Vice President of People & Talent
- Dr. Bill Harriman Ph.D.Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations
- Dr. Christel Iffland Ph.D.Senior Vice President of R&D Portfolio Management and Technology Operations
- Dr. Yasmina Noubia Abdiche Ph.D.Senior Vice President of Exploratory Research
- Dr. Bob Chen Ph.D.Senior Vice President of Discovery Systems
- Mr. Todd Pettingill C.F.A.Vice President of Business Development & Strategy